O Orexo AB
O
Closed
19.6 0.41
Overview
Share price change
24h
Min
19.32
Max
19.76
Income | 41M -75M |
|---|---|
Sales | 1.7M 5M |
EPS | -3.812 |
Profit margin | -1,500 |
Employees | 65 |
EBITDA | 206M -66M |
Next Earnings | 16 Jul 2026 |
|---|
Market Cap | -53M 647M |
|---|---|
Previous open | 19.19 |
Previous close | 19.6 |
Orexo AB Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Orexo AB Forecast
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Orexo AB
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis. In addition, its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
